Project description:We generated patient cSCC-derived xenografts (cSCC-PDXs) that recapitulate the histopathologic and molecular features of parental patient samples. Response to gefitinib treatment was tested in four independent models. cSCC34-PDXs showed intrinsic resistance to gefitinib, whereas three models (cSCC10-PDXs, cSCC16-PDXs and cSCC24-PDXs) initially showed a strong response to gefitinib, but acquired resistance after long-term treatment. RNA sequencing analysis were performed in matched untreated and gefitinib-resistant cSCC-PDXs to determine mechanisms behind gefitinib resistance.
Project description:To identify the therapeutic targets in a treatment-refractroy cancer patient, we performed single-cell RNA sequencing for 3,115 cells from primary bladder cancer (BC159-T#3) and patient-derived xenografts (BC159-T#3-PDX-vehicle and BC159-T#3-PDX-tipifarnib). Matched time-series bulk tumor tissues were also sequenced using whole exome target probe (WES) and whole transcriptome target probe (WTS).
Project description:To identify the therapeutic targets in a treatment-refractory cancer patient, we performed single-cell RNA sequencing for 3,115 cells from primary bladder cancer (BC159-T#3) and patient-derived xenografts (BC159-T#3-PDX-vehicle and BC159-T#3-PDX-tipifarnib). Matched time-series bulk tumor tissues were also sequenced using whole exome target probe (WES) and whole transcriptome target probe (WTS).
Project description:Patient derived xenografts (PDXs) of human EGFR-mutant lung cancer were propagated in mice and treated with osimertinib or control to investigate the transcriptional adaption resposne.
Project description:Researchers collect specimens from advanced or recurrent colorectal cancer (CRC) patients to conduct molecular profiling and establish tumor organoids (PDOs)/ patient-derived xenografts (PDXs). The aim of this study is to identify clinical actionable targets and predict in vivo response of the tumor to targeted drugs by using PDOs/ PDXs. And the above-mentioned studies will provide the patients with potential personalized cancer treatment options.
